



Atty. Dkt. No. 016777-0454

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Indu J. ISAACS
Title: GLP-2 FORMULATIONS
Appl. No.: 09/750,022
Filing Date: 12/29/2000
Examiner: Chih Min KAM
Art Unit: 1653

AMENDMENT AND REPLY UNDER 37 CFR § 1.111

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This communication is responsive to the non-final Office Action dated October 4, 2004, concerning the above-referenced patent application. As the shortened statutory period for response expires Tuesday, January 4, 2005, this response is timely filed.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this document.

Remarks begin on page 12 of this document.

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Previously Presented) A glucagon-like peptide 2 (GLP-2) formulation comprising:
 - (a) a medically useful amount of a naturally occurring GLP-2 or an analog thereof;
 - (b) a phosphate buffer in an amount sufficient to adjust the pH of the formulation to a physiologically tolerable level;
 - (c) L-histidine; and
 - (d) a bulking agent selected from the group consisting of mannitol and sucrose.
2. (Original) The GLP-2 formulation of claim 1, wherein the pH of the formulation is greater than about 6.0.
3. (Original) The GLP-2 formulation according to claim 2, wherein the pH of the formulation is from about 6.9 to about 7.9.
4. (Original) The GLP-2 formulation of claim 3, wherein the pH of the formulation is from about 7.3 to about 7.4.
5. (Original) The GLP-2 formulation of claim 1, wherein the GLP-2 peptide or analog thereof is present at a concentration of about 0.1 to about 50 mg/ml.
6. (Original) The GLP-2 formulation of claim 5, wherein the GLP-2 peptide or analog thereof is present at a concentration of about 5 to about 40 mg/ml.
7. (Original) The GLP-2 formulation of claim 6, wherein the GLP-2 peptide or analog thereof is present at a concentration of about 7 to about 30 mg/ml.
8. (Original) The GLP-2 formulation of claim 7, wherein the GLP-2 peptide or analog thereof is present at a concentration of about 10 to about 20 mg/ml.

9. (Original) The GLP-2 formulation of claim 8, wherein the L-histidine is present in an amount of about 0.5 to about 1%.
10. (Original) The GLP-2 formulation of claim 9, wherein the bulking agent is mannitol.
11. (Original) The GLP-2 formulation of claim 10, wherein the mannitol is present at a concentration of about 2 to about 5%.
12. (Original) The GLP-2 formulation of claim 11, wherein the mannitol is present at a concentration of about 2.5 to about 3.5%.
13. (Original) The GLP-2 formulation of claim 1, wherein the GLP-2 peptide is selected from the group consisting of a mammalian GLP-2 peptide, a vertebrate GLP-2 peptide, and a human GLP-2 peptide.
14. (Previously Presented) The GLP-2 formulation of claim 13, wherein the GLP-2 peptide has the sequence of a GLP-2 species from an animal selected from the group consisting of a primate, rat, mouse, porcine species, oxine species, bovine species, degu, hamster, guinea pig, fish, chicken, and human.
15. (Previously Presented) The GLP-2 formulation of claim 14, wherein the GLP-2 peptide is h(Gly2)GLP-2.
16. (Original) The GLP-2 formulation of claim 1, wherein the GLP-2 analog is identified by a process comprising:
 - (a) screening peptides against cells genetically engineered to produce the GLP-2 receptor, and
 - (b) identifying peptides which bind to the GLP-2 receptor, wherein such peptides are identified as GLP-2 peptides useful in the formulation of claim 1.

17. (Currently Amended) The GLP-2 formulation of claim 1, wherein the GLP-2 peptide is an analog of natural GLP-2, the analog having:
- (a) one or more amino acid substitutions, additions, deletions, or modifications; and
 - (b) GLP-2 receptor binding biological activity.
18. (Original) The GLP-2 formulation of claim 1, wherein the GLP-2 peptide is an analog which has been altered to confer resistance to endogenous enzymes.
19. (Original) The GLP-2 formulation of claim 18, wherein the alteration comprises substitution of the alanine residue at position 2 of GLP-2 with another suitable amino acid.
20. (Original) The GLP-2 formulation of claim 19, wherein the alanine residue at position 2 is substituted with glycine or serine.
21. (Original) The GLP-2 formulation of claim 1, wherein the GLP-2 analog is a GLP-2 receptor antagonist.
22. (Original) The GLP-2 formulation of claim 1 in lyophilized form.
23. (Original) The lyophilized formulations of claim 22, comprising less than about 5% water by weight.
24. (Original) The lyophilized formulations of claim 23, comprising 2% or less water by weight.
25. (Previously Presented) The GLP-2 formulation of claim 15, which is stable at ambient temperature for up to 6 months, as evidenced by GLP-2 peptide degradation of less than about 5% during this time period.
26. (Previously Presented) The GLP-2 formulation of claim 25, wherein less than about 4% peptide degradation is observed after storage of the GLP-2 formulation during the time period.

27. (Previously Presented) The GLP-2 formulation of claim 26, wherein less than about 2% peptide degradation is observed after storage of the GLP-2 formulation during the time period.

28. (Previously Presented) The GLP-2 formulation of claim 1, which is stable at a temperature of about 4°C for up to 18 months, as evidenced by GLP-2 peptide degradation of less than about 5% during this time period.

29. (Previously Presented) The GLP-2 formulation of claim 28, wherein less than about 4% peptide degradation is observed after storage of the GLP-2 during the time period.

30. (Original) The GLP-2 formulation of claim 29, wherein less than about 2% peptide degradation is observed after storage of the GLP-2 formulation during the time period.

31. (Original) A GLP-2 formulation comprising:
- (a) about 0.1 to about 50 mg/ml of a GLP-2 peptide or an analog thereof;
 - (b) a phosphate buffer in an amount sufficient to adjust the pH of the formulation to a pharmaceutically tolerable level;
 - (c) about 0.5 to about 1% L-histidine; and
 - (d) about 2 to about 5% mannitol.

32. (Previously Presented) The GLP-2 formulation of claim 31, wherein the GLP-2 is h(Gly2)GLP-2.

33. (Original) The GLP-2 formulation of claim 32, wherein the formulation is lyophilized.

34. (Original) The GLP-2 formulation of claim 32, wherein the pH of the formulation is selected from the group consisting of greater than about 6.0, and from about 6.9 to about 7.9.

35. (Original) The GLP-2 formulation of claim 34, wherein the pH of the formulation is from about 7.3 to about 7.4.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.